Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients

World Journal of Gastroenterology

Volumn 15, Issue 4, 2009, Pages 449-456

  Moehler, Markus ^a   Sprinzl, Martin F ^a   Abdelfattah, Murad ^b   Schimanski, Carl C ^a   Adami, Bernd ^b   Godderz, Werner ^b   Majer, Klaus ^c   Flieger, Dimitri ^d   Teufel, Andreas ^a   Siebler, Juergen ^a   Hoehler, Thomas ^e   Galle, Peter R ^a   Kanzler, Stephan ^f  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Outpatient Clinic   (Germany)

^c Outpatient Clinic of City Hospital   (Germany)

^d Gesundheits und Pflegezentrum Russelsheim   (Germany)

^e 1st Medical Department   (Germany)

^f Leopoldina Krankenhause   (Germany)

Author keywords

Bevacizumab; Capecitabine; First line therapy; Irinotecan; Metastatic colorectal cancer; Tumor response

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHOLINERGIC SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL TOXICITY; GERMANY; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOKALEMIA; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; OUTPATIENT CARE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEINURIA; SIDE EFFECT; STABLE ANGINA PECTORIS; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

EID: 59249096067     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.449     Document Type: Article

References (44)

1. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766-3775
2. Ishikawa T, Fukase Y, Yamamoto T, Sekiguchi F, Ishitsuka H. Antitumor activities of a novel fluoropyrimidine, N4pentyloxycarbonyl- 5′-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull 1998; 21: 713-717
3. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55: 1091-1097
4. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281
5. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Ann Oncol 2002; 13: 566-575
6. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292
7. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90: 1190-1197
8. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106
9. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115
10. Topham C, Moore J. Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer - a pilot study. Eur J Cancer Care (Engl) 1997; 6: 291-294
11. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947
12. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047
13. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914
14. Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Ruckle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Muller L, Genicot B, Anak O, Nordlinger B. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-4865
15. Moehler M, Hoffmann T, Zanke C, Hohl H, Burg H, Ehscheid P, Schwindt P, Adami B, Schroeder M, Klein O, Baldus M, Galle PR, Heike M. Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. Anticancer Drugs 2003; 14: 79-85
16. Teufel A, Steinmann S, Siebler J, Zanke C, Hohl H, Adami B, Schroeder M, Klein O, Hohler T, Galle PR, Heike M, Moehler M. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 2004; 4: 38
17. Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Canal P, Chatelut E, Guimbaud R, Cornen X. Dose escalation and pharmacokinetic study of capecitabine (Xeloda) and irinotecan (CPT-11) in gastrointestinal tumors: preliminary results. Proc Am Soc Clin Oncol 2002, 21: A397
18. Kerr DJ, Ten Bokkel Huinink WW, Ferry DR, Rea DW, Boussard BM, Oulid-Aissa D, Frings S, Nortier JW. A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002, 21: A643
19. Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17: 239-245
20. Tewes M, Schleucher N, Achterrath W, Wilke HJ, Frings S, Seeber S, Harstrick A, Rustum YM, Vanhoefer U. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Ann Oncol 2003; 14: 1442-1448
21. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100: 279-287
22. Grothey A, Jordan K, Kellner O, Constantin C, Dittrich G, Kroening H, Mantovani L, Schlichting C, Forstbauer H, Schmoll HJ. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2003, 22: A1022
23. Cartwright T, Lopez T, Vukelja SJ, Encarnacion C, Boehm KA, Asmar L. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 2005; 5: 50-56
24. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142
25. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007; 12: 443-450
26. Hurwitz H. New combinations in metastatic colorectal cancer: what are our expectations? Oncologist 2005; 10: 320-322
27. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol 2006, 24: A3510
28. Fernando N, Yu D, Morse M, Blobe G, Odogwu L, Crews J, Polito A, Honeycutt W, Franklin A, Hurwitz H. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. J Clin Oncol 2005, 23: A3556; updated information presented at meeting
29. Giantonio BJ, Levy DE, O'dwyer PJ, Meropol NJ, Catalano PJ, Benson AB 3rd. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006; 17: 1399-1403
30. Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn PJ, Dong W, Suzuki S, Sarkar S, Sugrue MM, Grothey A. Survival of patients (pts) with mCRC treated with bevacizumab in combination with chemotherapy: Results from the BRiTE registry. ASCO Gastrointestinal Cancer Symposium, 2007: A375; updated information presented at ASCO GI
31. Sobrero AF, Ackland S, Carrion RP, Chiara S, Clarke S, Giron CG, Langer B, Zurlo A, Young S. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol 2006, 24: A3544
32. Van Cutsem E, Michael M, Berry S, Bartolomeo M, Kretzschmar A, Rivera F, Lutiger B, Mazier M, Cunningham D. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC - First BEAT trial. ASCO Gastrointestinal Cancer Symposium, 2006: A250
33. Van Cutsem E, Michael M, Berry S, Dibartolomeo M, Rivera F, Kretzschmar A, Mazier M, Lutiger B, Cunningham D. Preliminary safety and efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI, and capecitabine for mCRC: First BEAT trial. ASCO Gastrointestinal Cancer Symposium, 2007: A346
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
35. Sobrero AF, Young S, Balcewicz M, Chiarra S, Perez Carrion R, Mainwaring P, Gapski J, Clarke S, Langer B, Ackland S. Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI. J Clin Oncol 2007; 25: A4068
36. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786
37. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
38. Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005; 16: 282-288
39. Reinacher-Schick AC, Kubicka S, Freier W, Arnold D, Dietrich G, Geissler M, Hegewisch-Becker S, Graeven U, Schmoll H, Schmiegel W: Activity of the combination of bevacizumab (Bev) with capecitabine/ irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol 2008; 26: A4030
40. Schmiegel WH, Reinacher-Schick A, Freier W, Dietrich G, Arnold D, Kanzler S, Geissler M, Graeven U, Hegewisch-Becker S, Schmoll H. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (Caplri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group. J Clin Oncol 2007; 25: A4034; Updated information presented at meeting
41. de Greve J, Kohne CH, Hartmann J, Lang I, Vergauwe P, Becker K, Braumann D. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer (CRC). Long-term results of the prospective multicenter EORTC phase III study 40015. J Clin Oncol 2006; 24: A3577; virtual presentation www.asco.org
42. Kohne CH, de Greve J, Bokemeyer C, Lang I, Vergauwe P, Braumann D, Debois M. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015. J Clin Oncol 2005; 23: A3525
43. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
44. Skillings JR, Johnson D, Miller K, Kabbinavar F, Bergsland E, Holmgren E, Holden S, Hurwitz H, Scappaticci F. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 2005, 23: A3019